Calculating the Social Cost of Illicit Drugs


Book Description

Social cost estimates are potentially a valuable source of informing policy makers on the impact of prevention, treatment and law enforcement strategies. However, estimating the social costs of illegal drug use poses a methodological challenge, given the difficulty of quantifying the link between drugs and their negative consequences and in assigning a monetary value to items that do not have market value. This study presents methodological guidance on developing indicators to calculate the social cost of drug abuse, mainly through a "cost-of-illness" approach. The document also contains two case studies of research projects in France that have applied a social-cost analysis to the use of alcohol and tobacco, and to illicit drugs.




Understanding the Demand for Illegal Drugs


Book Description

Despite efforts to reduce drug consumption in the United States over the past 35 years, drugs are just as cheap and available as they have ever been. Cocaine, heroin, and methamphetamines continue to cause great harm in the country, particularly in minority communities in the major cities. Marijuana use remains a part of adolescent development for about half of the country's young people, although there is controversy about the extent of its harm. Given the persistence of drug demand in the face of lengthy and expensive efforts to control the markets, the National Institute of Justice asked the National Research Council to undertake a study of current research on the demand for drugs in order to help better focus national efforts to reduce that demand. This study complements the 2003 book, Informing America's Policy on Illegal Drugs by giving more attention to the sources of demand and assessing the potential of demand-side interventions to make a substantial difference to the nation's drug problems. Understanding the Demand for Illegal Drugs therefore focuses tightly on demand models in the field of economics and evaluates the data needs for advancing this relatively undeveloped area of investigation.




The social cost of legal and illegal drugs in Belgium


Book Description

Alcohol, tobacco, illegal drugs and psychoactive medication (mis)use are associated with a higher likelihood of developing several diseases, (traffic) injuries and crimes. These substances reduce quality of life and increase the health care and law enforcement costs, productivity losses, etc. Consequently, the social and economic impact of substances on society is substantial. The SOCOST study estimates for the first time social costs for alcohol, tobacco, illegal drugs and psychoactive medication in Belgium for the year 2012. This cost-of-illness study presents the direct costs, the indirect cost as well as the intangible costs related to substance (mis)use. This research was commissioned by the Belgian Federal Science Policy Office (BELSPO) in the framework of the Federal Research Programme Drugs. Two universities cooperated: Ghent University, Institute for International Research on Criminal Policy (IRCP) and the Vrije Universiteit Brussel, Interuniversity Centre for Health Economics Research (I-CHER). The research was conducted under supervision of prof. dr. Freya Vander Laenen, prof. dr. Koen Putman, prof. dr. Lieven Pauwels, prof. dr. Wim Hardyns and prof. dr. Lieven Annemans.




Treating Drug Problems:


Book Description

Treating Drug Problems, Volume 2 presents a wealth of incisive and accessible information on the issue of drug abuse and treatment in America. Several papers lay bare the relationship between drug treatment and other aspects of drug policy, including a powerful overview of twentieth century narcotics use in America and a unique account of how the federal government has built and managed the drug treatment system from the 1960s to the present. Two papers focus on the criminal justice system. The remaining papers focus on Employer policies and practices toward illegal drugs. Patterns and cycles of cocaine use in subcultures and the popular culture. Drug treatment from a marketing, supply-and-demand perspective, including an analysis of policy options. Treating Drug Problems, Volume 2 provides important information to policy makers and administrators, drug treatment specialists, and researchers.




Making Medicines Affordable


Book Description

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.




Informatics, Management and Technology in Healthcare


Book Description

Biomedical informatics is becoming increasingly important as healthcare organizations worldwide implement biomedical informatics applications as part of their continued effort to improve the effectiveness of patient care and the efficiency of service delivery. This book presents the full papers delivered at the 2013 International Conference on Informatics, Management and Technology in Healthcare (ICIMTH 2013), held in Athens, Greece, in July 2013. The scope of biomedical informatics is very broad, including a number of technologies such as imaging, sensors, biomedical equipment and even organ transplant technology. The 90 papers included here examine research and applications outcomes - from cell to population - in these diverse fields, and because management and organizational issues play an important role in the implementation phase of biomedical informatics applications, these topics are also covered as an integral part of the theme. The book will be of interest to all those whose work involves the development and use of biomedical informatics applications.




Integrating Information Technology and Management for Quality of Care


Book Description

The impact of information technology on the management of healthcare has been enormous in recent years, and it continues to grow in scope and complexity. This book presents papers from the 2014 International Conference on Informatics, Management, and Technology in Healthcare (ICIMTH), held in Athens, Greece, in July 2014. The book includes 79 full papers and 12 poster presentations as well as keynotes, two workshops and three tutorials. Papers are divided into sections including: clinical informatics; decision support and intelligent systems; e-learning and education; health informatics, information management and technology assessment; healthcare IT; mobile technology in healthcare; public health informatics and issues; social and legal issues; and telemedicine. The book will be of interest to all those whose work involves the use of biomedical and health informatics.




International Guidelines for Estimating the Costs of Substance Abuse


Book Description

The International guidelines for estimating the costs of substance abuse presents a general framework for the development of cost estimates. A matrix of the types of costs to be considered is presented and there is a detailed discussion of the theoretical issues involved including: the definition of abuse determination of causality comparison of the demographic and human capital approaches to cost estimation the treatment and measurement of addictive consumption the treatment of private costs the measurement of intangible costs the treatment of non-workforce mortality and morbidity etc. Special considerations are discussed with regard to developing economies and drug-producing countries. The guidelines conclude with a brief discussion of future directions and the implications of these guidelines to research agendas and data collection systems.




Public expenditure on supply reduction policies


Book Description

Supply reduction is often the main approach used for addressing the illicit drug problem. – Pompidou Group Evaluating drug policy is an integral part of a cost-efficient approach to tackle illicit drugs. This report takes a first step towards a systematic analysis, by examining a set of representative attempts to estimate public expenditure on supply reduction interventions. It proposes a common set of definitions, aiming to establish a common basis for understanding this topic and facilitating comparability in three main dimensions: time, policy and countries. Although it is mainly confined to supply reduction expenditures, in order to set the context, it describes the proportion that total drugrelated expenditure represents of national public spending and presents the balance between demand and supply reduction spending for a number of European countries. Finally, with the aim of facilitating and promoting future empirical expenditure studies and of setting the ground for the development of good practices, relevant data sources and methodologies applied are listed and discussed and examples of sectorial models of public spending are selectively provided.




Facing Addiction in America


Book Description

All across the United States, individuals, families, communities, and health care systems are struggling to cope with substance use, misuse, and substance use disorders. Substance misuse and substance use disorders have devastating effects, disrupt the future plans of too many young people, and all too often, end lives prematurely and tragically. Substance misuse is a major public health challenge and a priority for our nation to address. The effects of substance use are cumulative and costly for our society, placing burdens on workplaces, the health care system, families, states, and communities. The Report discusses opportunities to bring substance use disorder treatment and mainstream health care systems into alignment so that they can address a person's overall health, rather than a substance misuse or a physical health condition alone or in isolation. It also provides suggestions and recommendations for action that everyone-individuals, families, community leaders, law enforcement, health care professionals, policymakers, and researchers-can take to prevent substance misuse and reduce its consequences.